The toxicities associated with specific immunotherapy targets can be unpredictable, such as the higher risk of ICANS in CD19-targeting therapies than CD20-targeting therapies, and even the unique neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR T-cell therapy in multiple myeloma (96). This evidence concerns the gene TNFRSF17 and AL amyloidosis.